1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

Summary

Sales of dyslipidemia therapeutics is estimated to be approximately $11.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The dyslipidemia market will grow at a strong CAGR of 10.1% over the forecast period, reaching sales of $29.2B by 2025. The US is the largest market for dyslipidemia therapies, contributing approximately 61.5% of total sales in the base year. GlobalData expects uptake of the revolutionary class of PCSK9 targeting biologics to be the strongest driver of growth in the dyslipidemia market in the 7MM, reaching peak sales of $9.5B in 2025.

Major drivers of Dyslipidemia market growth over the forecast period are -
- The launches of three PCSK9 inhibitors-Amgen’s Repatha, Sanofi and Regeneron’s Praluent, and Eli Lilly’s LY3015014-which will significantly boost market growth.
- The launch of several add-on therapies, including Esperion Therapeutic’s ETC-1002 and Merck and Amgen’s cholesteryl ester transfer protein (CETP) inhibitors
- Increase in global prevalence of dyslipidemia, coupled with growing awareness of the disease.

Although the dyslipidemia market has numerous well-established therapies and the pipeline is promising, there is a considerable level of unmet need. Patient compliance, cost-effective therapies, and drugs targeting rare diseases represent major unmet needs in the dyslipidemia space. Patient compliance remains the biggest issue, and a major contributing factor to this is the asymptomatic nature of this disease, as well as the burden of taking several pills daily to treat this disease.

In addition to this, many patients discontinue therapy, which puts them at considerable risk of experiencing a CV event. The PCSK9 monoclonal antibodies (mAbs), Repatha and Praluent, are expected to address the compliance issue due to their less frequent dosing schedules; however, KOLs indicated that patient education and enhanced disease awareness are important issues that also need to be addressed. While patient education is not a common area of focus for pharmaceutical companies, it’s clear that if diagnosis rates and patient compliance were increased, then this would translate to a boost in drug use and sales.

Companies reviewed in this report: Abbvie, Aegerion Pharmaceuticals Inc., Akcea Therapeutics Inc., Amarin, Amgen, AstraZeneca, Cerenis Therapeutics Inc., Daiichi Sankyo, Eli Lilly, Esperion Therapeutics Inc., Genzyme, Ionis Pharmaceuticals, Merck & Co., Regeneron Pharmaceuticals Inc., Sanofi, The Medicine Company.

Scope
- Overview of dyslipidemia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized dyslipidemia therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the dyslipidemia therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global dyslipidemia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the dyslipidemia therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the dyslipidemia therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the 7MM dyslipidemia therapeutics market from 2015-2025.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table Of Contents

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 19
1.2 List of Figures 24
2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 27
3 Disease Overview 28
3.1 Etiology and Pathophysiology 28
3.1.1 Etiology 28
3.1.2 Pathophysiology 30
3.2 Symptoms 34
3.3 Prognosis 34
3.4 Quality of Life 34
4 Epidemiology 35
4.1 Disease Background 35
4.2 Risk Factors and Comorbidities 35
4.3 Global Trends 37
4.4 Forecast Methodology 37
4.4.1 Sources Used Tables 37
4.4.2 Forecast Assumptions and Methods 42
4.4.3 Sources Not Used 58
4.5 Epidemiological Forecast for Dyslipidemia (2015-2025) 59
4.5.1 Dyslipidemia 59
4.5.2 Familial Hypercholesterolemia 63
4.5.3 Increased Low-Density Lipoprotein Cholesterol 64
4.5.4 High Triglycerides 69
4.5.5 Very High Triglycerides 74
4.5.6 Low High-Density Lipoprotein Cholesterol 76
4.6 Discussion 81
4.6.1 Epidemiological Forecast Insight 81
4.6.2 Limitations of the Analysis 83
4.6.3 Strengths of the Analysis 84
5 Disease Management 85
5.1 Diagnosis and Treatment Overview 85
5.1.1 Diagnosis 85
5.1.2 Treatment Guidelines and Leading Prescribed Drugs 87
5.1.3 Clinical Practice 90
5.2 US 92
5.3 5EU 94
5.4 Japan 97
6 Competitive Assessment 99
6.1 Overview 99
6.2 Statins 102
6.2.1 Overview of drug class 102
6.2.2 Crestor (Rosuvastatin) 104
6.3 Zetia (Ezetimibe) 110
6.3.1 Overview 110
6.3.2 Efficacy 113
6.3.3 Safety 114
6.3.4 SWOT Analysis 116
6.3.5 Forecast 116
6.4 Praluent (Alirocumab) 117
6.4.1 Overview 117
6.4.2 Efficacy 120
6.4.3 Safety 122
6.4.4 SWOT Analysis 123
6.4.5 Forecast 124
6.5 Repatha (Evolocumab) 125
6.5.1 Overview 125
6.5.2 Efficacy 127
6.5.3 Safety 130
6.5.4 SWOT Analysis 131
6.5.5 Forecast 132
6.6 Vytorin (Simvastatin/Ezetimibe) 132
6.6.1 Overview 132
6.6.2 Efficacy 134
6.6.3 Safety 135
6.6.4 SWOT Analysis 135
6.6.5 Forecast 136
6.7 Kynamro (Mipomersen) 136
6.7.1 Overview 136
6.7.2 Efficacy 138
6.7.3 Safety 139
6.7.4 SWOT Analysis 141
6.7.5 Forecast 141
6.8 Juxtapid (Lomitapide) 142
6.8.1 Overview 142
6.8.2 Efficacy 144
6.8.3 Safety 146
6.8.4 SWOT Analysis 147
6.8.5 Forecast 147
6.9 Niacin/Nicotinic Acid 148
6.9.1 Overview 148
6.9.2 Efficacy 150
6.9.3 Safety 152
6.9.4 SWOT Analysis 153
6.9.5 Forecast 153
6.10 Fibrates 153
6.10.1 Overview of Drug Class 153
6.10.2 Tricor/Trilipix (Fenofibrate/Fenofibric acid) 155
6.11 Omega-3 Fatty Acids 159
6.11.1 Overview 159
6.11.2 Lovaza (omega-3 acid ethyl esters) 160
6.11.3 Vascepa (Icosapent Ethyl) 163
6.11.4 Epanova (omega-3 carboxylic acids) 168
6.12 Bile Acid Sequestrants 172
6.12.1 Overview 172
6.12.2 Efficacy 174
6.12.3 Safety 174
6.12.4 SWOT Analysis 175
6.12.5 Forecast 175
7 Unmet Needs Assessment and Opportunity Analysis 176
7.1 Overview 176
7.2 Therapies that Target Lipoprotein(a) 178
7.2.1 Unmet Need 178
7.2.2 Gap Analysis 179
7.2.3 Opportunity 180
7.3 Cost-Effective Therapies for Dyslipidemia 180
7.3.1 Unmet Need 180
7.3.2 Gap Analysis 181
7.3.3 Opportunity 181
7.4 Efficacious TG-Lowering Therapies 182
7.4.1 Unmet Need 182
7.4.2 Gap Analysis 183
7.4.3 Opportunity 184
7.5 Improved Diagnosis, Patient Education, and Long-Term Compliance 185
7.5.1 Unmet Need 185
7.5.2 Gap Analysis 187
7.5.3 Opportunity 188
7.6 HoFH Therapies with Reduced Side Effects 189
7.6.1 Unmet Need 189
7.6.2 Gap Analysis 190
7.6.3 Opportunity 191
7.7 Therapies that Prevent or Reverse the Buildup of Atherosclerotic Plaque 191
7.7.1 Unmet Need 191
7.7.2 Gap Analysis 192
7.7.3 Opportunity 193
8 Pipeline Assessment 194
8.1 Overview 194
8.2 Promising Drugs in Clinical Development 195
8.2.1 LY3015014 197
8.2.2 Anacetrapib 202
8.2.3 AMG-899 (TA-8995/DEZ-001) 210
8.2.4 Bempedoic Acid (ETC-1002) 216
8.2.5 Volanesorsen 223
8.2.6 CER-001 228
8.2.7 ALN-PCSsc 233
8.2.8 Gemcabene 238
8.2.9 Pemafibrate (K-877) 243
8.3 Other Drugs in Development 248
9 Current and Future Players 250
9.1 Overview 250
9.2 Trends in Corporate Strategy 253
9.3 Company Profiles 255
9.3.1 AbbVie 255
9.3.2 Aegerion Pharmaceuticals, Inc. 257
9.3.3 Akcea Therapeutics, Inc. and Ionis Pharmaceuticals 258
9.3.4 Amarin 260
9.3.5 Amgen 262
9.3.6 AstraZeneca 263
9.3.7 Cerenis Therapeutics, Inc. 265
9.3.8 Daiichi Sankyo 266
9.3.9 Eli Lilly 267
9.3.10 Esperion Therapeutics, Inc. 269
9.3.11 Genzyme 270
9.3.12 Merck and Co. 272
9.3.13 Regeneron Pharmaceuticals, Inc. 274
9.3.14 Sanofi 275
9.3.15 The Medicines Company 277
10 Market Outlook 280
10.1 Global Markets 280
10.1.1 Forecast 280
10.1.2 Drivers and Barriers - Global Issues 285
10.2 US 290
10.2.1 Forecast 290
10.2.2 Key Events 293
10.2.3 Drivers and Barriers 294
10.3 5EU 296
10.3.1 Forecast 296
10.3.2 Key Events 298
10.3.3 Drivers and Barriers 299
10.4 Japan 302
10.4.1 Forecast 302
10.4.2 Key Events 304
10.4.3 Drivers and Barriers 305
11 Appendix 308
11.1 Bibliography 308
11.2 Abbreviations 332
11.3 Methodology 338
11.4 Forecasting Methodology 338
11.4.1 Diagnosed Dyslipidemia Patients 338
11.4.2 Percent Drug-Treated Patients 339
11.4.3 Drugs Included in Each Therapeutic Class 339
11.4.4 Launch and Patent Expiry Dates 340
11.4.5 General Pricing Assumptions 341
11.4.6 Individual Drug Assumptions 342
11.4.7 Generic Erosion 348
11.4.8 Pricing of Pipeline Agents 348
11.5 Primary Research - KOLs Interviewed for this Report 349
11.6 Primary Research - Prescriber Survey 351
11.7 About the Authors 352
11.7.1 Analyst 352
11.7.2 Therapy Area Director 352
11.7.3 Epidemiologist 353
11.7.4 Director of Epidemiology 353
11.7.5 Global Director of Therapy Analysis and Epidemiology 354
11.8 About GlobalData 355
11.9 Disclaimer 355

1.1 List of Tables
Table 1: Dyslipidemia: Fredrickson Classification System 28
Table 2: Risk Factors and Comorbidities for Dyslipidemia 36
Table 3: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Dyslipidemia 38
Table 4: 8MM, Sources Used to Forecast the Total Prevalent Cases of FH 39
Table 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of Increased LDL-C 40
Table 6: 8MM, Sources Used to Forecast the Total Prevalent Cases of High TG 41
Table 7: 8MM, Sources Used to Forecast the Total Prevalent Cases of Low HDL-C 42
Table 8: 8MM, Total Prevalent Cases of Dyslipidemia, Ages ?20 Years, Both Sexes, N, Selected Years 2015-2025 60
Table 9: 8MM, Diagnosed Prevalent Cases of Dyslipidemia, Ages ?20 Years, Both Sexes, N, Selected Years 2015-2025 62
Table 10: 8MM, Total Prevalent Cases of Increased LDL-C, Ages ?20 Years, Both Sexes, N, Selected Years, 2015-2025 65
Table 11: 8MM, Total Prevalent Cases of High TG, Ages ?20 Years, Both Sexes, N, Selected Years, 2015-2025 70
Table 12: 8MM, Total Prevalent Cases of Very High TG, Ages ?20 Years, Both Sexes, N, Selected Years, 2015-2025 75
Table 13: 8MM, Total Prevalent Cases of Low HDL-C, Ages ?20 Years, Both Sexes, N, Selected Years 2015-2025 77
Table 14: AACE Optimal/Near-Optimal, Borderline, and High-Risk Serum Lipid Concentrations 85
Table 15: Factors Considered for Different CVD Risk Calculators 86
Table 16: Treatment Guidelines for Dyslipidemia 88
Table 17: Most Prescribed Drugs for Dyslipidemia by Class in the Global Markets, 2015 90
Table 18: Country Profile - US 93
Table 19: Market Profile - 5EU 95
Table 20: Country Profile - Japan 98
Table 21: Intensity level of commonly used statins 103
Table 22: Product Profile - Crestor (Rosuvastatin) 106
Table 23: Efficacy of Rosuvastatin - Lipid and Lipoprotein Parameters 107
Table 24: Crestor SWOT Analysis, 2015 109
Table 25: Product Profile - Zetia 112
Table 26: Efficacy of Zetia - Primary and Secondary Endpoints, IMPROVE-IT study 114
Table 27: Safety of Zetia (Ezetimibe) 115
Table 28: Drug Zetia (Ezetimibe) SWOT Analysis, 2015-2025 116
Table 29: Product Profile - Praluent 120
Table 30: Efficacy of Praluent (alirocumab) - Primary and Secondary Endpoints, ODYSSEY LONG TERM Phase III Study 121
Table 31: Safety of Praluent (alirocumab) 122
Table 32: Praluent (Alirocumab) SWOT Analysis, 2015-2025 123
Table 33: Product Profile - Repatha 127
Table 34: Pivotal Trials of Repatha (Evolocumab) 128
Table 35: Repatha (Evolocumab) SWOT Analysis, 2015-2025 131
Table 36: Product Profile - Vytorin 133
Table 37: Efficacy of Vytorin - Primary and Secondary Endpoints, VYVA study 134
Table 38: Vytorin SWOT Analysis, 2015 135
Table 39: Product Profile - Kynamro 138
Table 40: Efficacy of Kynamro - Lipid and Lipoprotein Parameters, RADICHOL 1 Phase III Study 139
Table 41: Safety of Kynamro (mipomersen) 140
Table 42: Kynamro SWOT Analysis, 2015 141
Table 43: Product Profile - Juxtapid 144
Table 44: Efficacy of Juxtapid - Lipid and Lipoprotein parameters, Phase III Study 145
Table 45: Juxtapid SWOT Analysis, 2015 147
Table 46: Product Profile - Niaspan 150
Table 47: Niacin/Nicotinic Acid SWOT Analysis, 2015 153
Table 48: Summary of the Therapeutic Properties of Fibrates* 154
Table 49: Product Profile - Tricor/Trilipix 156
Table 50: Tricor/Trilipix SWOT Analysis, 2015 158
Table 51: Product Profile - Lovaza 161
Table 52: Efficacy of Lovaza - Pivotal Studies for the Treatment of Very High TGs 162
Table 53: Lovaza SWOT Analysis, 2015 163
Table 54: Product Profile - Vascepa 165
Table 55: Efficacy of Vascepa - ANCHOR Phase III Study 166
Table 56: Vascepa SWOT Analysis, 2015 167
Table 57: Product Profile - Epanova 169
Table 58: Efficacy of Epanova - ESPRIT Phase III Study 170
Table 59: Epanova SWOT Analysis, 2015 171
Table 60: Product Profile - Welchol 173
Table 61: Efficacy of Welchol - GLOWS Study 174
Table 62: Welchol SWOT Analysis, 2015 175
Table 63: Unmet Need and Opportunity in Dyslipidemia, 2015 178
Table 64: Product Profile - LY3015014 198
Table 65: Efficacy of LY3015014 199
Table 66: LY3015014 SWOT Analysis, 2015 201
Table 67: Product Profile - Anacetrapib 205
Table 68: Efficacy of Anacetrapib - Primary and Secondary Endpoints, DEFINE study 206
Table 69: Safety of Anacetrapib - AEs and Safety Variables, DEFINE study 207
Table 70: Anacetrapib SWOT Analysis, 2015 209
Table 71: Product Profile - AMG-899 ( TA-8995/DEZ-001) 211
Table 72: Efficacy of TA-8995 - Primary Endpoints, TULIP study 213
Table 73: AMG-899 SWOT Analysis, 2015 215
Table 74: Product Profile - ETC-1002 (Bempedoic Acid) 218
Table 75: Efficacy of ETC-1002 - Lipid and lipoprotein parameters 220
Table 76: ETC-1002 SWOT Analysis, 2015 222
Table 77: Product Profile - Volanesorsen 224
Table 78: Efficacy of Volanesorsen - Lipid and Lipoprotein Levels and Glycemic Control 225
Table 79: Volanesorsen SWOT Analysis, 2015 227
Table 80: Product Profile - CER-001 229
Table 81: Efficacy of CER-001 230
Table 82: CER-001 SWOT Analysis, 2015 232
Table 83: Product Profile - ALN-PCSsc 234
Table 84: ALN-PCSsc SWOT Analysis, 2015 237
Table 85: Product Profile - Gemcabene 239
Table 86: Efficacy of Gemcabene 240
Table 87: Gemcabene SWOT Analysis, 2015 242
Table 88: Product Profile - Pemafibrate 244
Table 89: Efficacy of Pemafibrate 245
Table 90: Safety of Pemafibrate 246
Table 91: Pemafibrate SWOT Analysis, 2015 247
Table 92: Drugs in Development for Dyslipidemia, 2015 249
Table 93: Key Companies in the Dyslipidemia Market in the 7MM, 2015 252
Table 94: Abbvie's Dyslipidemia Portfolio Assessment, 2015 257
Table 95: Aegerion Pharmaceuticals' Dyslipidemia Portfolio Assessment, 2015 258
Table 96: Ionis Pharmaceuticals' Dyslipidemia Portfolio Assessment, 2015 260
Table 97: Amarin's Dyslipidemia Portfolio Assessment, 2015 262
Table 98: Amgen's Dyslipidemia Portfolio Assessment, 2015 263
Table 99: AstraZeneca's Dyslipidemia Portfolio Assessment, 2015 264
Table 100: Cerenis Therapeutics' Dyslipidemia Portfolio Assessment, 2015 266
Table 101: Daiichi Sankyo's Dyslipidemia Portfolio Assessment, 2015 267
Table 102: Eli Lilly's Dyslipidemia Portfolio Assessment, 2015 269
Table 103: Esperion Therapeutics' Dyslipidemia Portfolio Assessment, 2015 270
Table 104: Genzyme's Dyslipidemia Portfolio Assessment, 2015 272
Table 105: Merck and Co.'s Dyslipidemia Portfolio Assessment, 2015 273
Table 106: Regeneron Pharmaceuticals' Dyslipidemia Portfolio Assessment, 2015 275
Table 107: Sanofi's Dyslipidemia Portfolio Assessment, 2015 277
Table 108: The Medicines Company's Dyslipidemia Portfolio Assessment, 2015 279
Table 109: Dyslipidemia Market - Global Drivers and Barriers, 2015?2025 285
Table 110: Key Events Impacting Sales for Dyslipidemia in the US, 2015-2025 293
Table 111: Dyslipidemia Market - Drivers and Barriers in the US, 2015?2025 294
Table 112: Key Events Impacting Sales for Dyslipidemia in the 5EU, 2015-2025 298
Table 113: Dyslipidemia Market - Drivers and Barriers in the 5EU, 2015?2025 299
Table 114: National Healthcare Authorities in the 5EU Nations 299
Table 115: National Public Health Initiatives in the 5EU Nations 300
Table 116: Governmental Drug Pricing Authorities in the 5EU Nations 301
Table 117: Key Events Impacting Sales for Dyslipidemia in Japan, 2015-2025 304
Table 118: Dyslipidemia Market - Drivers and Barriers in Japan, 2015?2025 305
Table 119: Key Launch Dates for Dyslipidemia 340
Table 120: Key Patent Expiry Dates for Dyslipidemia 340
Table 121: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 351

1.2 List of Figures
Figure 1: Classification of Dyslipidemia 30
Figure 2: 8MM Total Prevalent Cases of Dyslipidemia, Ages ?20 Years, Both Sexes, N, 2015-2025 61
Figure 3: 8MM Diagnosed Prevalent Cases of Dyslipidemia, Ages ?20 Years, Both Sexes, N, 2015-2025 63
Figure 4: 8MM, Total Prevalent Cases of FH, Both Sexes, Ages ?20 Years, N, 2015 and 2025 64
Figure 5: 8MM, Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ?20 Years, N, 2015 and 2025 66
Figure 6: 8MM, Sex-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ?20 Years, N, 2015 67
Figure 7: 8MM, Age-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages ?20 Years, 2015 68
Figure 8: 8MM, Age-Standardized Total Prevalence of Increased LDL-C, Both Sexes, Ages ?20 Years, 2015 69
Figure 9: 8MM, Total Prevalent Cases of High TG, Both Sexes, Ages ?20 Years, N, 2015-2025 71
Figure 10: 8MM, Sex-Specific Total Prevalent Cases of High TG, Both Sexes, Ages ?20 Years, N, 2015 72
Figure 11: 8MM, Age-Specific Total Prevalent Cases of High TG, Both Sexes, Ages ?20 Years, 2015 73
Figure 12: 8MM, Age-Standardized Total Prevalence of High TG, Both Sexes, Ages ?20 Years, 2015 74
Figure 13: 8MM, Total Prevalent Cases of Very High TG, Both Sexes, Ages ?20 Years, N, 2015-2025 76
Figure 14: 8MM, Total Prevalent Cases of Low HDL-C, Both Sexes, Ages ?20 Years, N, 2015-2025 78
Figure 15: 8MM, Sex-Specific Total Prevalent Cases of Low HDL-C, Ages ?20 Years, N, 2015 79
Figure 16: 8MM, Age-Specific Total Prevalent Cases of Low HDL-C, Both Sexes, Ages ?20 Years, 2015 80
Figure 17: 8MM, Age-Standardized Total Prevalence of Low HDL-C, Both Sexes, Ages ?20 Years, 2015 81
Figure 18: Statin Mechanism of Action 103
Figure 19: Competitive Assessment of Late-Stage Pipeline Agents in Dyslipidemia, 2015-2025 197
Figure 20: ACL inhibition 217
Figure 21: Company Portfolio Gap Analysis in Dyslipidemia, 2015-2025 253
Figure 22: Global Sales for Dyslipidemia by Region, 2015 and 2025 283
Figure 23: Global Sales for Dyslipidemia by Drug Class, 2015 and 2025 284
Figure 24: Global Sales for PCSK9 targeting therapies, 2015-2025 285
Figure 25: Sales for Dyslipidemia by Drug Class in the US, 2015 and 2025 292
Figure 26: Sales for Dyslipidemia by Drug Class in the 5EU, 2015 and 2025 297
Figure 27: Sales for Dyslipidemia by Drug Class in Japan, 2015 and 2025 303

Companies Mentioned
AbbVie
Aegerion Pharmaceuticals, Inc.
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals
Amarin
Amgen
AstraZeneca
Cerenis Therapeutics, Inc.
Daiichi Sankyo
Eli Lilly
Esperion Therapeutics, Inc.
Genzyme
Merck and Co.
Regeneron Pharmaceuticals, Inc.
Sanofi
The Medicines Company

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cholesterol Screening/ Cholesterol Lab Testing Services Market by Type of Customer, Geography & Qualitative Assessment - Forecasts to 2021

Cholesterol Screening/ Cholesterol Lab Testing Services Market by Type of Customer, Geography & Qualitative Assessment - Forecasts to 2021

  • $ 5650
  • Industry report
  • January 2017
  • by MarketsandMarkets

The global cholesterol testing services market is expected to reach USD 17.5 billion by 2021 from USD 11.9 billion in 2016, growing at a CAGR of 8% during the forecast period. This market is segmented ...

Dyslipidemia  - Market Insights, Epidemiology and Market Forecast-2023

Dyslipidemia  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Dyslipidemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2025

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2025

  • $ 3995
  • Industry report
  • December 2016
  • by GlobalData

EpiCast Report: Dyslipidemia - Epidemiology Forecast to 2025 Summary Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascula ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.